Josip A. Borovac et al. also demonstrated that the use of SGLT2 inhibitors was comparable to the placebo regarding the risk of UTI events in HF patients (relative risk [RR]: 1.09; 95% confidence interval [CI]: 0.94–1.26; p = 0.24) [41]. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.